BOSTON, June 3, 2019 /PRNewswire/ -- Proteostasis
Therapeutics, Inc. (NASDAQ: PTI), a clinical stage
biopharmaceutical company dedicated to the discovery and
development of groundbreaking therapies to treat cystic fibrosis
(CF) and other diseases caused by dysfunctional protein processing,
today announced that data from the Company's CF clinical
development programs will be presented during three panel
presentations at the 42nd European Cystic Fibrosis
Society (ECFS) Conference on June 5-8,
2019 at the Arena and Convention Centre Liverpool in
Liverpool, United Kingdom. The
Company will also host an educational symposium on Wednesday, June 5th from 4:00 to 5:30 p.m. BST, which will be located in
Hall 1C.
The event, titled "Reshaping the Landscape of Cystic Fibrosis
Treatment Options for People with Cystic Fibrosis – Novel CFTR
Modulator Combinations," will feature presentations by key opinion
leaders, including:
- Patrick Flume, M.D.
Professor of Medicine and
Pediatrics, Medical University of South
Carolina
Title: The Evolving CFTR Modulator
Landscape
- Jane Davies,
M.D.
Professor of Paediatric Respirology, Imperial
College School of Medicine
Title: Unmet Needs – The Patient
Experience
- Damian Downey,
M.D.
Clinical Senior Lecturer in Respiratory Medicine,
Queen's University Belfast
Title: New CFTR Modulator
Combinations – New Possibilities
- Jeffrey Beekman,
Ph.D.
Associate Professor & Director of CF
Research Lab of Department of Pediatrics, University Medical Center
Utrecht
Title: Personalized Approach to CFTR Modulator
Therapy
Details for the presentations are as follows:
Title: Initial Results Evaluating Combinations of
the Novel CFTR Corrector PTI-801, Potentiator PTI-808, and
Amplifier PTI-428 in CF Subjects
Presenter: Damian Downey, M.D., Clinical Senior
Lecturer in Respiratory Medicine, Queen's University Belfast,
Belfast, UK
Session Title: Hot off the press: new data from drug
trials
Date and time: Thursday, June 6, 2019 from 5:00-6:30 p.m. BST
Location: Hall 1A
Title: Initial Results Evaluating the Add-On Effect
of the Novel CFTR Corrector PTI-801 in CF Subjects
Presenter: Manu Jain, M.D., Professor of Medicine
(Pulmonary and Critical Care) and Pediatrics, Northwestern Medicine
(Feinberg School of Medicine),
Chicago, IL, US
Session Title: Hot off the press: new data from drug
trials
Date and time: Thursday, June 6, 2019 from 5:00-6:30 p.m. BST
Location: Hall 1A
Title: Initial Results Evaluating the Novel CFTR
Corrector PTI-801, Potentiator PTI-808, and Amplifier PTI-428 in
F508del Homozygous CF Subjects
Presenter: Geoffrey Gilmartin, M.D., Chief Medical
Affairs Officer, Proteostasis, Boston,
MA, US
Session Title: Late Breaking Science
Date and time: Friday, June 7, 2019 from 5:00-6:30 p.m. BST
Location: Hall 1C
Following the presentations at ECFS, the PTI presentations will
be available on the Investor Events page in the Investors &
Media section of the Company's
website, www.proteostasis.com.
For more information on this meeting, visit:
https://www.ecfs.eu/liverpool2019.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage
biopharmaceutical company developing small molecule therapeutics to
treat cystic fibrosis and other diseases caused by dysfunctional
protein processing. Headquartered in Boston, MA,
the Proteostasis Therapeutics team focuses on identifying
therapies that restore protein function. For more information,
visit www.proteostasis.com.
Safe Harbor
To the extent that statements in this release are not historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as "aim," "may," "will," "expect,"
"anticipate," "estimate," "intend," and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. Examples of forward-looking statements
made in this release include, without limitation, statements
regarding the expected presentations at an upcoming
conference. Forward-looking statements made in this release
involve substantial risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by the
forward-looking statements, and we, therefore cannot assure you
that our plans, intentions, expectations or strategies will be
attained or achieved. Such risks and uncertainties include,
without limitation, the uncertainties inherent in the execution and
completion of clinical trials, in the timing of availability of
trial data, in the results of the clinical trials, in the actions
of regulatory agencies, in the commercialization and acceptance of
new therapies, and those set forth in our Annual Report on Form
10-K for the year ended December 31, 2018, our Quarterly
Report on form 10-Q for the quarter ended March 31, 2019, and
our other SEC filings. We assume no obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
CONTACTS:
Investors:
David Pitts
/ Claudia Styslinger
Argot Partners
212.600.1902
david@argotpartners.com / claudia@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-announces-presentations-and-hosts-educational-symposium-at-the-42nd-european-cystic-fibrosis-conference-300860462.html
SOURCE Proteostasis Therapeutics, Inc.